Public health implications for adequate transitional care for HIV-infected prisoners: five essential components
- PMID: 21844030
- PMCID: PMC3156144
- DOI: 10.1093/cid/cir446
Public health implications for adequate transitional care for HIV-infected prisoners: five essential components
Erratum in
- Clin Infect Dis. 2011 Oct;53(8):851
Abstract
In the United States, 10 million inmates are released every year, and human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) prevalence is several-fold greater in criminal justice populations than in the community. Few effective linkage-to-the-community programs are currently available for prisoners infected with HIV. As a result, combination antiretroviral therapy (cART) is seldom continued after release, and virological and immunological outcomes worsen. Poor HIV treatment outcomes result from a myriad of obstacles that released prisoners face upon reentering the community, including homelessness, lack of medical insurance, relapse to drug and alcohol use, and mental illness. This article will focus on 5 distinct factors that contribute significantly to treatment outcomes for released prisoners infected with HIV and have profound individual and public health implications: (1) adaptation of case management services to facilitate linkage to care; (2) continuity of cART; (3) treatment of substance use disorders; (4) continuity of mental illness treatment; and (5) reducing HIV-associated risk-taking behaviors as part of secondary prevention.
Figures
References
-
- Montaner JS, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531–6. - PubMed
-
- Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. - PubMed
-
- Maruschak L, Beavers R. HIV in prisons, 2007–08. Washington, DC: U.S. Department of Justice, Office of Justice Programs; 2009.
Publication types
MeSH terms
Substances
Grants and funding
- R01 DA030762/DA/NIDA NIH HHS/United States
- R01 DA025943/DA/NIDA NIH HHS/United States
- R01 AA018944/AA/NIAAA NIH HHS/United States
- H79TI019806/TI/CSAT SAMHSA HHS/United States
- U90HA07632/PHS HHS/United States
- UR6PS000391/PS/NCHHSTP CDC HHS/United States
- R21 DA019843/DA/NIDA NIH HHS/United States
- R01 DA017059/DA/NIDA NIH HHS/United States
- K24 DA017072/DA/NIDA NIH HHS/United States
- K02 DA032322/DA/NIDA NIH HHS/United States
- T32 MH020031/MH/NIMH NIH HHS/United States
- H97 HA 08541/PHS HHS/United States
- UR6 PS000391/PS/NCHHSTP CDC HHS/United States
- K23 DA019381/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
